A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

In a randomized trial, 48 weeks of treatment with bulevirtide, which inhibits hepatitis D virus entry into hepatocytes, reduced HDV RNA and alanine aminotransferase levels in patients with chronic hepatitis D.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 389; no. 1; pp. 22 - 32
Main Authors:	Wedemeyer, Heiner, Aleman, Soo, Brunetto, Maurizia Rossana, Blank, Antje, Andreone, Pietro, Bogomolov, Pavel, Chulanov, Vladimir, Mamonova, Nina, Geyvandova, Natalia, Morozov, Viacheslav, Sagalova, Olga, Stepanova, Tatyana, Berger, Annemarie, Manuilov, Dmitry, Suri, Vithika, An, Qi, Da, Ben, Flaherty, John, Osinusi, Anu, Liu, Yang, Merle, Uta, Schulze zur Wiesch, Julian, Zeuzem, Stefan, Ciesek, Sandra, Cornberg, Markus, Lampertico, Pietro
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 06.07.2023
Subjects:	Alanine transaminase Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Arthralgia Asthenia Biopsy Cirrhosis Coinfection - drug therapy Coinfection - virology Disease Eosinophilia FDA approval Gastroenterology Gastroenterology General Hepatitis B Hepatitis B surface antigen Hepatitis B Surface Antigens Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatitis D, Chronic - drug therapy Hepatitis delta virus Hepatitis Delta Virus - genetics Hepatocytes Humans Infections Infectious Disease Infectious Disease General Interferon Liver cirrhosis Liver Disease Liver diseases Pruritus Ribonucleic acid RNA Viral Infections Russia
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!